Loading
Old version — revision 1
This is a fixed snapshot of Methuselah Foundation, saved by Import as part of the initial corpus import. It is not edited and it is not updated; the article may have changed since.
Edit summary: Initial import of content/methuselah-foundation.md — the filesystem corpus, unchanged. Not an edit.
A Virginia nonprofit founded in the early 2000s that used prize competitions to seed research on life extension, regenerative medicine and organ engineering.
Methuselah Foundation is a nonprofit organization founded in the early 2000s by the entrepreneur David Gobel and the biogerontologist Aubrey de Grey to accelerate research on extending healthy human life, principally by running prize competitions. Its stated mission is to "make 90 the new 50 by 2030". It is best known for the Mprize, which rewarded record-setting mouse longevity, and for the New Organ prizes in regenerative medicine, and it spun out the SENS Research Foundation in 2009.
The foundation's method is deliberate: identify a bottleneck, define a measurable target, and offer money for hitting it rather than for proposing to try. Prizes shift the risk from funder to competitor, attract entrants a grant committee would not select, and produce a public benchmark. They also work only where the target is unambiguous, which has constrained what the foundation could take on.
Its second function has been convening. For most of the 2000s, when aging research attracted little private money, the foundation was one of very few places where researchers, donors and advocates in the field met at all, and a substantial share of the modern longevity ecosystem traces to those connections.
The Methuselah Mouse Prize, launched in 2003 and usually shortened to the Mprize, is the organization's signature programme. It awarded money in two categories, and the distinction between them was the point.
The longevity prize went to the oldest mouse ever recorded, by any means. Andrzej Bartke won it in 2003 with a growth-hormone-receptor-deficient dwarf mouse that lived beyond 1,800 days; his group's report of the underlying strain remains one of the largest proportional lifespan extensions recorded in a mammal.1
The rejuvenation prize was the more interesting design. It required the intervention to begin in middle age, which excludes developmental manipulations and lifelong regimens and demands that something be done to an already-aged animal. Stephen Spindler won it in 2004 with late-onset Caloric restriction.
Why late-onset matteredA drug that must be given from birth is not a medicine anyone can take. By paying only for interventions started after middle age, the rejuvenation prize enforced the constraint that separates a laboratory result from a possible therapy, and it did so a decade before the field generally adopted it. Nearly every intervention now taken seriously in aging biology is assessed on late-onset dosing.
The Mprize's leaderboard was never displaced by a wide margin, which is itself a finding. Two decades of work on mouse longevity has not produced an intervention that dramatically exceeds what dwarf mutants and caloric restriction achieved, and the strongest pharmacological signal in the field — Rapamycin fed to genetically heterogeneous mice starting in late life, in the National Institute on Aging's Interventions Testing Program — produced extensions measured in percentages rather than multiples.2
From 2014 the foundation extended the prize model to regenerative medicine under the New Organ banner, motivated by the Organ shortage arithmetic: transplant waiting lists are limited by donor supply, and no amount of surgical improvement changes that.
The New Organ Liver Prize offered a seven-figure award for a bioengineered liver that could sustain a large animal for a defined period. It went unclaimed, which is an accurate reflection of where Organ bioprinting and Tissue engineering stand: vascularization at scale remains unsolved, and no whole solid organ has been grown and successfully transplanted.
The foundation also partnered with NASA on the Vascular Tissue Challenge, a competition to produce thick, metabolically functional vascularized human tissue that survives in the laboratory for a month. That prize was awarded in 2021 to a team from Wake Forest, and it is the clearest demonstration that a well-specified target in this area can be met.
A related programme, the Organ Preservation Alliance, worked on extending the viability window for donated organs — the problem that vitrification and normothermic perfusion research addresses, and one where progress has real near-term clinical value regardless of what one believes about life extension.
The foundation is philanthropically funded, and its most consequential single gift was from Peter Thiel in 2006 — several million dollars at a time when almost no private capital of that size was directed at aging. The gift mattered less for its amount than for its signalling effect on other technology donors, and much of the money that later founded Calico Life Sciences, Altos Labs and Retro Biosciences came from the same social network.
The organization later established the Methuselah Fund, a venture vehicle that invests in early-stage longevity and regenerative medicine companies, on the reasoning that some of the field's bottlenecks are commercial rather than scientific and that a nonprofit prize cannot address them.
The foundation has attracted less criticism than most organizations in the field, largely because prizes make weaker claims than research programmes do. A prize does not assert that a result is achievable; it offers money if someone achieves it.
The substantive criticism is about proportion. The sums involved are small — hundreds of thousands to low millions of dollars — relative to the cost of the work being incentivized, and the prizes have generally been won by researchers who were already doing the work rather than attracting new entrants. The Mprize's most-cited effect was reputational: it gave mouse longevity research a public scoreboard and made the field legible to donors.
A second criticism concerns the mission statement. "Make 90 the new 50 by 2030" is not a testable proposition, has no operational definition in terms of Healthspan or function, and as of 2026 no route to meeting it on that timeline has been described. The foundation has continued to use it, which its critics read as the same rhetorical looseness that characterizes the Longevity escape velocity literature more generally.
Methuselah's importance is as an origin point. It funded de Grey's early work, including the period in which he assembled the damage-repair framework later set out in Ending Aging,3 then spun out the organization that carried it, seeded the donor relationships that made large-scale private longevity funding possible, and demonstrated that prizes could operate in biology where they had previously been used mainly in aerospace — a lesson XPRIZE Healthspan applied two decades later at far larger scale.
What it did not do is produce a therapy, which is the correct standard by which to judge a research funder and the one on which the entire field, not just this organization, has so far failed. The open question for the prize model in biology is whether the endpoints that matter can be specified precisely enough to compete over. A mouse's age is unambiguous. Restored human function is not, and every attempt to define it — including the current one — has had to invent its own measures.
paperBartke, A. et al. "Extending the lifespan of long-lived mice." Nature, 2001.↩The record rests on a germline dwarfing mutation present from birth, which is the case the prize's separate rejuvenation category was written to exclude.
paperHarrison, D.E. et al. "Rapamycin fed late in life extends lifespan in genetically heterogeneous mice." Nature, 2009.↩Run at three independent sites on genetically heterogeneous mice, with dosing begun in late life; the gain is a percentage of median lifespan.
bookde Grey, A. and Rae, M. Ending Aging: The Rejuvenation Breakthroughs That Could Reverse Human Aging in Our Lifetime. St. Martin's Press, 2007.↩A popular exposition of the author's own research agenda; it sets out a programme rather than reporting results.